Benefits of Sustained Upregulated Unimolecular GLP-1 and CCK Receptor Signalling in Obesity-Diabetes by Tanday, Neil et al.







University of Ottawa, Canada
Yutaka Seino,
Kansai Electric Power Medical





This article was submitted to
Gut Endocrinology,
a section of the journal
Frontiers in Endocrinology
Received: 01 March 2021
Accepted: 29 April 2021
Published: 14 May 2021
Citation:
Tanday N, English A, Lafferty RA,
Flatt PR and Irwin N (2021) Benefits of
Sustained Upregulated Unimolecular





published: 14 May 2021
doi: 10.3389/fendo.2021.674704Benefits of Sustained Upregulated
Unimolecular GLP-1 and CCK
Receptor Signalling in
Obesity-Diabetes
Neil Tanday, Andrew English, Ryan A. Lafferty , Peter R. Flatt and Nigel Irwin*
Diabetes Research Group, School of Biomedical Sciences, Ulster University, Coleraine, United Kingdom
Combined activation of GLP-1 and CCK1 receptors has potential to synergistically
augment the appetite-suppressive and glucose homeostatic actions of the individual
parent peptides. In the current study, pancreatic beta-cell benefits of combined GLP-1
and CCK1 receptor upregulation were established, before characterising bioactivity and
antidiabetic efficacy of an acylated dual-acting GLP-1/CCK hybrid peptide, namely
[Lys12Pal]Ex-4/CCK. Both exendin-4 and CCK exhibited (p<0.001) proliferative and
anti-apoptotic effects in BRIN BD11 beta-cells. Proliferative benefits were significantly
(p<0.01) augmented by combined peptide treatment when compared to either parent
peptide alone. These effects were linked to increases (p<0.001) in GLUT2 and
glucokinase beta-cell gene expression, with decreased (p<0.05-p<0.001) expression of
NFkB and BAX. [Lys12Pal]Ex-4/CCK exhibited prominent insulinotropic actions in vitro,
coupled with beneficial (p<0.001) satiety and glucose homeostatic effects in the mice, with
bioactivity evident 24 h after administration. Following twice daily injection of [Lys12Pal]Ex-
4/CCK for 28 days in diabetic high fat fed (HFF) mice with streptozotocin (STZ)-induced
compromised beta-cells, there were clear reductions (p<0.05-p<0.001) in energy intake
and body weight. Circulating glucose was returned to lean control concentrations, with
associated increases (p<0.001) in plasma and pancreatic insulin levels. Glucose tolerance
and insulin secretory responsiveness were significantly (p<0.05-p<0.001) improved by
hybrid peptide therapy. In keeping with this, evaluation of pancreatic histology revealed
restoration of normal islet alpha- to beta-cell ratios and reduction (p<0.01) in centralised
islet glucagon staining. Improvements in pancreatic islet morphology were associated
with increased (p<0.05) proliferation and reduced (p<0.001) apoptosis of beta-cells.
Together, these data highlight the effectiveness of sustained dual GLP-1 and CCK1
receptor activation by [Lys12Pal]Ex-4/CCK for the treatment of obesity-related diabetes.
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Tanday et al. An Acylated GLP-1/CCK Hybrid PeptideINTRODUCTION
The increasing use of GLP-1 mimetics to treat diabetes and
obesity highlights the therapeutic importance of this class of
drugs (1). Indeed, weight loss recently reported using the GLP-1
mimetic semaglutide in humans with obesity is highly impressive
(2). Nevertheless, the pronounced metabolic benefits of bariatric
surgery, often resulting in remission of diabetes, unquestionably
exceed positive effects of GLP-1 mimetics, highlighting the
important interplay between gut-derived hormones to induce
distinct and sustained benefits in obesity-diabetes (3). In full
agreement, administration of GLP-1 mimetics in combination
with related gut-derived hormones imparts metabolic advantages
beyond that seen with GLP-1 alone (4, 5). Recent advances in
peptide drug design have also witnessed generation of several
unimolecular dual- or triple-acting hybrid peptides, that contain
a GLP-1 backbone structure (6). For example, Tirzepatide, a
synthetic dual-acting GIP and GLP-1 receptor agonist,
demonstrates remarkable antidiabetic effectiveness in phase II
clinical trials (7). With such successes in mind, a strong rational
exists for generating unimolecular agents that mimic meal-
induced gut hormone release by co-activating receptors for
GLP-1 plus other hormones involved in conveying the
metabolic and satiety signals initiated by feeding.
Cholecystokinin (CCK) is a hormone primarily secreted from
gastrointestinal I-cells as well as neurons of the enteric and
central nervous systems (8). The peptide circulates in various
molecular forms, with the octapeptide CCK-8 being the smallest
form to exhibit full biological activity (9). To impart its
physiological actions, CCK binds and activates specific
receptors, namely CCK1 and CCK2, that modulate various
physiological processes including satiety, pancreatic endocrine,
and exocrine function as well as gastric acid and bile secretion
(8). In particular, CCK-based regulation of energy intake and
pancreatic endocrine islet function make the hormone a
potentially attractive therapeutic agent for obesity and diabetes
(9). As such, CCK dose-dependently inhibits food intake
consistently across species, from rodents (10) to non-human
primates (11) and humans (12) mediated via CCK1 receptors
(13). CCK also stimulates insulin secretion in rodents and
humans (14, 15), with sustained administration of a long-
acting CCK1 selective receptor agonist exerting notable
metabolic benefits in rodent models of type 2 diabetes (16, 17).
In agreement, transgenic mice with genetically-induced CCK
ablation (18) or overexpression (19) exhibit impaired or
improved beta-cell function, respectively. Moreover, CCK has
recently been shown to exert important beta-cell proliferative
and anti-apoptotic effects (20), which might counter beta-cell
loss in diabetes.
When taken together, the biological action profile of CCK has
strong parallels with those of GLP-1 (9). Both hormones initiate
separate, but complementary, cell signalling pathways via
phospholipase C or adenylate cyclase, respectively (21). At the
level of the pancreatic beta-cell an important GLP-1/CCK intra-
islet loop has also been described that helps protect against beta-
cell apoptosis, with obvious benefits for diabetes (21). Thus, it is
unsurprising that combined activation of CCK1 and GLP-1Frontiers in Endocrinology | www.frontiersin.org 2receptors has been noted to induce numerous benefits on body
weight reduction and blood glucose control (22–24). Preliminary
studies also provide proof-of-principle evidence for this
therapeut ic approach, both in terms of combined
administration of individual long-acting GLP-1 and CCK1
agonists (5, 25), as well as dual-acting hybrid peptides (26, 27).
This is highly relevant for clinical translation since methods to
augment the antidiabetic effectiveness of approved GLP-1
therapeutics are much sought after (28).
Two separate dual-acting GLP-1/CCK fusion peptides have been
described to date, with both exerting remarkable benefits on body
weight reduction and pancreatic islet morphology, resulting in
improved metabolic control in obese high fat fed mice (26, 27).
Although uncharacterised in terms of in vivo islet effects, the fusion
peptide described by Hornigold and colleagues (27) appeared to
have the most attractive biological action profile, with confirmed
balance between GLP-1 and CCK1 receptor activation. Based on
this knowledge, and to progress attractiveness of the GLP-1/CCK
hybrid peptide approach, we employed acylation of this molecule to
create a compound capable of sustained, simultaneous activation of
GLP-1 and CCK1 receptors, namely [Lys12Pal]Ex-4/CCK, with a
pharmacodynamic profile more suitable for clinical development.
Thus, a C-16 fatty acid was conjugated to the free amino group of
Lys12 in the GLP-1/CCK hybrid peptide via a glutamyl linker
(Table 1).
Our primary objective was to examine the therapeutic efficacy
and islet cell morphology after 28 days twice daily treatment with
[Lys12Pal]Ex-4/CCK in high fat fed (HFF) mice with limited beta-
cell compensation induced by low-dose STZ administration. Prior
to this, bioactivity of [Lys12Pal]Ex-4/CCK was established in BRIN
BD11 beta-cells, alongside assessment of acute and more
prolonged in vivo effects on satiety and glucose homeostasis in
mice. In addition, the positive interplay between GLP-1 and CCK
receptor signalling on beta-cell growth and survival, with related
impact on gene expression, was also studied. Ultimately, our data
confirm that the profound beneficial pharmacological effects of
combined activation GLP-1 and CCK receptor pathways in
obesity-diabetes can be effectively harnessed within an
appropriately designed single long-acting hybrid peptide.METHODS
Peptides
[Lys12Pal]Ex-4/CCK (Table 1) and related peptides were
synthesised by Synpeptide (Shanghai, China) at 95% purity





A-V-R-L-F-I-E-W-L-K-N-[PEG4]-Nle-G-W-K-D-NmeFSequence of [Lys12Pal]Ex-4/CCK using one letter amino acid notation. The C-16 fatty acid
residue in [Lys12Pal]Ex-4/CCK is attached to Lys12 using a gamma-glutamyl spacer.
Polyethylene glycol 4 (PEG4) is used as a linker. Nle, norleucine; NMeF, N-
methylphenylalanine.May 2021 | Volume 12 | Article 674704
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conducted (4).
In Vitro Effects of GLP-1 and CCK1
Receptor Activation on Beta-Cell Gene
Expression, Proliferation, and Apoptosis
Initial studies examined the impact of upregulated GLP-1 and
CCK1 receptor signalling on the expression of key genes involved
in insulin secretion and cell survival in BRIN BD11 beta-cells (29).
Messenger RNA (mRNA) was isolated from cells (150,000 cells)
following 18 h incubation with exendin-4, CCK-8, or a
combination of both peptides (all at 10-6 M) using the RNeasy
mini kit (Qiagen, UK) following manufacturer’s protocols.
Utilising SuperScript™ II Reverse Transcriptase (Invitrogen Life
Technologies, Carlsbad, CA, USA), mRNA was converted to
cDNA as described previously. Expression of genes associated
with apoptosis (BAX and NFkB) and insulin secretion (Glut2 and
Glucokinase) were determined by quantitative real-time PCR,
normalised to internal house-keeping control GAPDH (30).
Primer sequences for genes studied were as previously described
from our laboratory (31). To assess beta-cell proliferative effects,
BRIN-BD11 cells (150,000 cells per chamber slide) were
incubated for 18 h with test peptides (10-6 M) before fixation in
paraformaldehyde and staining for Ki-67 (Ab15580, AbCam).
Likewise, to assess effects on protection against apoptosis, cells
were cultured in cytokine mix (IL-1b 100U/ml, IFN-g 20
U/ml, TNF-a 200 U/ml) alone or with test peptides for 18 h,
prior to fixation and staining for TUNEL using an in-situ death
detection kit (in situ cell death kit, Fluorescein; Roche
Diagnostics). Both Ki-67 and TUNEL stained cells were imaged
using a fluorescence microscope (Olympus system microscope,
model BX51) fitted with DAPI (350 nm), FITC (488 nm) and
TRITC (594 nm) filters and an Olympus XM10 camera system.
In Vitro Effects of [Lys12Pal]Ex-4/CCK
on Insulin Secretion
To examine effects of [Lys12Pal]Ex-4/CCK on insulin secretion,
BRIN-BD11 cells were seeded at a density of 150,000 cells per
well into 24-well plates and allowed to attach overnight.
Following a 40-minute preincubation (1.1 mM glucose KRB
buffer), cells were incubated with KRB buffer (16.7 mM
glucose) with [Lys12Pal]Ex-4/CCK or exendin-4 (10-6 M). In a
second experiment cells were incubated with classical
modulators of insulin secretion in combination with [Lys12Pal]
Ex-4/CCK or exendin-4 (each at 10-6 M). For all experiments,
BRIN-BD11 cells were incubated under test conditions for a 20-
minute period at 37°C, with the resulting supernatant collected
and insulin content assessed by radioimmunoassay (32).
Acute In Vivo Experiments
Acute in vivo studies were carried out using 10-week-old adult
male C57BL/6 mice (Envigo Ltd, UK). Mice were single-housed
and kept in a temperature-controlled environment (22 ± 2°C)
under a 12-hour light/dark cycle, with ad libitum access to
drinking water and maintenance diet (10% fat, 30% protein
and 60% carbohydrate, percent of total energy 12.99 kJ/g; TrouwFrontiers in Endocrinology | www.frontiersin.org 3Nutrition, UK). All experiments were approved by Ulster
University Animal Ethics Review Committee and conducted in
accordance with the UK Animals (Scientific Procedures) Act
1986. To assess effects of [Lys12Pal]Ex-4/CCK on food intake in
overnight (18 hour) fasted mice, mice (n=8) were administered
with an intraperitoneal (i.p.) injection of saline vehicle (0.9%
[w/v] NaCl) or [Lys12Pal]Ex-4/CCK (25 nmol/kg bw) and
cumulative food consumption recorded at regular intervals
over a 180 min observation period. Acute effects of [Lys12Pal]
Ex-4/CCK on glucose homeostasis were also assessed in
overnight fasted mice, following an i.p. injection of glucose
alone (18 mmol/kg bw) or in combination with [Lys12Pal]Ex-4/
CCK (25 nmol/kg bw). More persistent effects on feeding and
glucose tolerance were examined as above, but with peptide
injected 4, 8, 12 or 24 h prior to feeding or administration of
glucose, as appropriate. In a separate series of experiments, the
impact of established GLP-1 and CCK1 receptor antagonists
(both at 25 nmol/kg bw), namely exendin(9-39) and SR27897
(Tocris Bioscience, Bristol, UK) respectively, on [Lys12Pal]Ex-4/
CCK induced (25 nmol/kg bw) satiety was examined.Chronic In Vivo Experiments
Adult male NIH Swiss mice (12-week-old), were maintained for
3 weeks on high fat diet (45% fat, 20% protein, 35%
carbohydrate; percent of total energy 26.15 kJ/g; Dietex
International Ltd., Witham, UK). After this period, they were
administered three once weekly i.p. injections of streptozotocin
(4-hour fast, 50 mg/kg bw, dissolved in sodium citrate buffer, pH
4.5) on weeks 3, 4 and 5. Starting on week 6, diabetic mice (non-
fasting glycaemia >11.1 mmol/l) were grouped (n=8) and
received twice-daily intraperitoneal injections (08:00 and 20:00)
of saline vehicle (0.9% [w/v] NaCl) or [Lys12Pal]Ex-4/CCK (25
nmol/kg bw) for 28 days. Mice were continued on high fat diet
throughout the experiment. At regular intervals, cumulative
energy intake and body weight were assessed, with circulating
glucose, insulin and glucagon measured on day 28. At the end of
the treatment period, glucose tolerance (18 mmol/kg bw; i.p.;
18-h fasted) and insulin sensitivity (25 U/kg bovine insulin; i.p.;
non-fasted) tests were conducted. Terminal analyses involved
dissection of pancreatic tissue, which was processed for
quantification of hormone content or pancreatic islet
morphology, following acid ethanol protein extraction or
fixation in 4% PFA, respectively (33).Biochemical Analyses
Blood samples were obtained from conscious mice via the cut tip on
the tail vein and blood glucose immediately measured using an
Ascencia Contour blood glucose meter (Bayer Healthcare Newbury,
UK). Blood was collected in chilled heparin/fluoride coated micro-
centrifuge tubes (Sarstedt, Numbrecht, Germany) and centrifuged
for 15 minutes at 12,000 rpm using a Beckman microcentrifuge
(Beckman Instruments, Galway, Ireland) to separate plasma. Insulin
and glucagon were then measured by radioimmunoassay (32) or
commercially available ELISA (EZGLU-30K, Merck Millipore,
Burlington, Massachusetts), respectively.May 2021 | Volume 12 | Article 674704
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Immunohistochemistry was used to examine islet morphology
by staining for insulin (1:400; ab6995, AbCam) or glucagon
(1:1000; ab92517, AbCam). Image analysis was carried out using
CellF image analysis software (Olympus Soft Imaging Solutions,
GmbH, Münster, Germany). To assess islet morphology, areas of
insulin and glucagon positive staining were quantified using a
“closed polygon” and expressed as islet/beta-/alpha- cell areas in
µm2, as described previously (34). To assess beta-cell
proliferation and apoptosis, co-staining of insulin with Ki-67
(1:400; ab15580, AbCam) or TUNEL (In situ cell death kit,
Fluorescein; Roche Diagnostics) was conducted. For
quantification, the number of insulin-positive cells co-
expressing Ki-67 or TUNEL respectively were counted using
ImageJ software, with >80 islets analysed per treatment group. In
all cases, following incubation with primary antibodies, the
following secondary antibodies Alexa Fluor594 goat anti-
mouse IgG and Alexa Fluor488 goat anti-rabbit, were used as
appropriate (1:400; ThermoFisher Scientific). Slides underwent a
final incubation with DAPI before being mounted for imaging
using a fluorescence microscope (Olympus system microscope,
model BX51) fitted with DAPI (350 nm), FITC (488 nm) and
TRITC (594 nm) filters and an Olympus XM10 camera system.
Statistical Analyses
Statistical tests were conducted using GraphPad PRISM software
(Version 5.0). Values are expressed as mean ± SEM.
Comparative analyses between groups were performed using a
one-way ANOVA with Bonferroni’s post hoc test, a two-way
ANOVA with Bonferroni’s post hoc test or Student’s unpaired
t-test, as appropriate. Differences were deemed significant
if p<0.05.RESULTS
Effects of Individual and Combined
Upregulation of GLP-1 and CCK1
Receptors on Beta-Cell Proliferation
and Apoptosis, as well as Related
Gene Expression
Exendin-4 and CCK-8 increased (p<0.001) BRIN-BD11 beta-cell
proliferation (Figure 1A). More interestingly, co-incubation of
exendin-4 with CCK-8 induced greater beta-cell proliferative
effects when compared to exendin-4 (p<0.01) or CCK-8
(p<0.001) alone (Figure 1A). Likewise, both peptides reduced
(p<0.001) cytokine-induced BRIN-BD11 cell apoptosis, with
combined exendin-4 and CCK-8 treatment evoking
comparable benefits to the parent peptides alone (Figure 1B).
Representative images of BRIN-BD11 cells stained for Ki-67 or
TUNEL under each incubation condition are presented in
Figures 1C, D, respectively. Exendin-4 and CCK-8 had no
significant effect of Glut2 expression following an 18 h
incubation in BRIN BD11 beta-cells, but combined peptide
treatment significantly increased Glut2 mRNA levels when
compared to exendin-4 (p<0.001) or CCK-8 (p<0.05) aloneFrontiers in Endocrinology | www.frontiersin.org 4(Figure 1E). Whilst CCK-8 decreased (p<0.05) glucokinase
expression, combined treatment with exendin-4 increased
glucokinase gene expression compared to exendin-4 (p<0.05)
or CCK-8 (p<0.001) alone (Figure 1F). Both CCK-8 alone, and
in combination with exendin-4, decreased (p<0.01) NFkB
expression (Figure 1G). Neither exendin-4 nor CCK-8 alone
significantly affected Bax expression in BRIN BD11 cells, but
combined peptide treatment resulted in a significant (p<0.05)
decrease in Bax mRNA levels (Figure 1H).
In Vitro Insulinotropic Actions of [Lys12Pal]
Ex-4/CCK
Similar to exendin-4, and to a lesser extent CCK-8, [Lys12Pal]Ex-
4/CCK augmented (p<0.05 – p<0.01) 16.7 mM glucose-induced
insulin release from BRIN-BD11 cells at a concentration of
10-6 M (Figure 2A). [Lys12Pal]Ex-4/CCK and exendin-4 also
exerted relatively similar insulin secretory potentiating actions
(p<0.001) on the stimulatory effects of key modulators of insulin
release, namely 16.7 mM glucose, 10 mM alanine, 7.68 mM Ca2+
and 10 nM PMA (Figure 2B).
Acute Effects of [Lys12Pal]Ex-4/CCK on
Food Intake and Glucose Tolerance
When injected i.p. in overnight fasted mice, [Lys12Pal]Ex-4/CCK
reduced (p<0.05) food intake at all observation points from
90 min onwards (Figure 3A). Moreover, [Lys12Pal]Ex-4/CCK
displayed persistent satiety effects in mice when administered 4
(p<0.001) or (p<0.05) 8 h prior to feeding (Figures 3B, C). When
[Lys12Pal]Ex-4/CCK was delivered 12 h prior to feeding, the
ability to inhibit food intake were no longer apparent
(Figure 3D). Studies with GLP-1 and CCK1 receptor
antagonists suggested that the satiating actions of [Lys12Pal]Ex-4/
CCK were dependent on both GLP-1 and CCK1 receptor
signalling, with perhaps marginally more reliance on GLP-1
receptor signalling in this regard (Figure 3E). When injected
co-jointly with glucose [Lys12Pal]Ex-4/CCK reduced (p<0.05)
individual and AUC glucose values, but this was not associated
with demonstrably increased plasma insulin concentrations
(Figures 4A, B). However, administration of [Lys12Pal]Ex-4/
CCK either 4, 8 or 12 h prior to the glucose challenge resulted in
robust (p<0.01–p<0.001) glucose-lowering and insulin secretory
actions (Figures 4C–H). Interestingly, [Lys12Pal]Ex-4/CCK still
possessed significant (p<0.001) glucose homeostatic effects when
administered 24 h prior to glucose (Figure 4I), although no
demonstrable change of glucose-induced insulin release was
observed at this time (Figures 4I–J). This contrasts with the
comparatively transient effects of native exendin-4 and CCK-8 as
reported previously (16, 35).
Effects of [Lys12Pal]Ex-4/CCK on Body
Weight, Food Intake as well as Circulating
Glucose, Insulin, and Glucagon
Twice daily treatment with [Lys12Pal]Ex-4/CCK in HFF mice
with STZ-induced compromised beta-cells, namely HFF-STZ
mice, resulted in significant (p<0.05) weight loss on day 7, that
persisted until the end of the study (Figure 5A). Interestingly,May 2021 | Volume 12 | Article 674704
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likely as a result of treatment regimen acclimatisation, with body
weights of saline treated mice then stabilising compared with a
continued gradual reduction of weight in mice receiving
[Lys12Pal]Ex-4/CCK (Figure 5A). Indeed, when body weight
change over the 28 days was analysed, only [Lys12Pal]Ex-4/CCK
treated HFF-STZ mice presented with a reduction (p<0.05) in
body weight gain (Figure 5B). [Lys12Pal]Ex-4/CCK induced
body weight reductions were associated with consistent
decreases (p<0.05-p<0.001) in energy intake (Figure 5C). On
day 28, circulating glucose in [Lys12Pal]Ex-4/CCK HFF-STZ
mice was similar to lean controls, and significantly (p<0.001)
reduced when compared to HFF-STZ control mice (Figure 5D).
Corresponding plasma insulin levels were decreased in HFF-STZ
control mice, and elevated (p<0.01) to levels above lean controlsFrontiers in Endocrinology | www.frontiersin.org 5by [Lys12Pal]Ex-4/CCK intervention (Figure 5E). Interestingly,
plasma glucagon was not different between lean and diabetic
control mice on day 28, but [Lys12Pal]Ex-4/CCK decreased
(p<0.05) circulating glucagon when compared to HFF-STZ
control mice (Figure 5F).Effects of [Lys12Pal]Ex-4/CCK on Glucose
Tolerance, Insulin Sensitivity, and
Pancreatic Insulin and Glucagon Content
Following a glucose challenge on day 28, [Lys12Pal]Ex-4/CCK
mice presented with substantially (p<0.001) improved glucose
homeostasis (Figures 6A, B), that was associated with a
significant (p<0.05) augmentation of glucose-induced insulin
release (Figures 6C, D), when compared to HFF control miceA
C
D
E F G H
B
FIGURE 1 | Effects of exendin-4, CCK-8, and a combination of both peptides on BRIN-BD11 proliferation, apoptosis, and expression of key genes. (A, B) To
assess effects on BRIN BD11 beta-cell proliferation and apoptosis, cells were incubated with test peptides (10-6 M) alone, or together with cytokine mix (CM; IL-1b
100U/ml, IFN-g 20 U/ml, TNF-a 200 U/ml) where specified, for 18 h prior to staining for (A) Ki-67 or (B) TUNEL. Representative images show cells stained for
(C) Ki-67 (red) and (D) TUNEL (green) with DAPI (blue), with arrows indicating positively stained cells. (E–H) qPCR analysis of Glut2, glucokinase, NFkB and Bax
mRNA expression following 18 h incubation with test peptides (10-6 M) in BRIN BD11 beta-cells. All gene expression data was normalised to GAPDH housekeeping
control. Values are mean ± SEM (n=4). lllp < 0.001 compared to untreated controls. FFFp < 0.001 compared to cytokine mix. *p < 0.05, **p < 0.01, ***p < 0.001
compared to exendin-4 alone. Dp < 0.05 and DDDp < 0.001 compared to CCK-8 alone.May 2021 | Volume 12 | Article 674704
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tolerance and insulin secretion were still impaired (p<0.001) in
[Lys12Pal]Ex-4/CCK HFF-STZ mice when compared to lean
controls (Figures 6A, D). On first inspection, peripheral
insulin sensitivity appeared to be largely unaffected by
[Lys12Pal]Ex-4/CCK treatment, but when considered as
glycaemic response with AAC analysis, a clear improvement
(p<0.01) was evident (Figures 6E, F). This improvement
appeared to be partly driven by clear reductions of non-fasting
glucose levels evoked by 28 days treatment with [Lys12Pal]Ex-4/
CCK in HFF/STZ mice. Pancreatic insulin content was elevated
(p<0.01), and glucagon content decreased (p<0.001), in
[Lys12Pal]Ex-4/CCK treated mice when compared to HFF-STZ
controls, with values not significantly different from lean control
mice (Figures 6G, H).
Effects of [Lys12Pal]Ex-4/CCK on
Pancreatic Islet Morphology as well as
Beta-Cell Proliferation and Apoptosis
HFF-STZ mice had reduced (p<0.001) islet and beta-cell areas,
that were not significantly affected by [Lys12Pal]Ex-4/CCKFrontiers in Endocrinology | www.frontiersin.org 6treatment (Figures 7A, B). However, elevations (p<0.001) of
alpha-cell area in HFF-STZ mice were fully reversed by
[Lys12Pal]Ex-4/CCK treatment (Figure 7C), which was
associated with a trend towards normalisation of alpha:beta
ratio in these mice (Figure 7D). Moreover, the characteristic
appearance of increased glucagon staining within the centre of
islets in HFF-STZ mice was reversed by [Lys12Pal]Ex-4/CCK
treatment (Figure 7E). In addition, beta-cell proliferation was
increased (p<0.05) and beta-cell apoptosis decreased (p<0.001),
respectively, by [Lys12Pal]Ex-4/CCK treatment compared to
HFF/STZ mice (Figures 7F, G), with beta-cell proliferation
also increased (p<0.001) when compared to lean control mice
(Figure 7F). Representative images of islets stained for insulin
and glucagon as well as insulin and Ki-67 or insulin and TUNEL
are presented in Figures 7H–J.DISCUSSION
Additive, and frequently synergistic, benefits on satiety and
pancreatic endocrine function by combined GLP-1 and CCK1A
B
FIGURE 2 | Effects of exendin-4, CCK-8 or [Lys12Pal]Ex-4/CCK on insulin release from rodent BRIN-BD11 cells. (A) Cells were incubated (20 min) with 16.7 mM
glucose alone and with exendin-4, CCK-8 or [Lys12Pal]Ex-4/CCK (10-6 M) and insulin secretion assessed by RIA. (B) Effects of exendin-4 or [Lys12Pal]Ex-4/CCK (10-6 M)
on the secretory action of established modulators of insulin secretion in BRIN BD11 cells. Values are mean ± SEM (n=8). *p < 0.05, **p < 0.01 and ***p < 0.001
compared with (A) 16.7 mM glucose alone or (B) insulinotropic agent with peptide.May 2021 | Volume 12 | Article 674704
Tanday et al. An Acylated GLP-1/CCK Hybrid Peptidereceptor activation have been documented previously (23, 36). In
the current study, we have exploited this in terms of realising a
new avenue for the treatment of T2DM. First, we examined the
potential benefits of upregulated GLP-1 and CCK1 receptor
activation on pancreatic beta-cells, given the recent
observations that CCK may be less influential in terms of
augmenting GLP-1 induced beta-cell insulin secretion (37).
This is an important aspect to understand because GLP-1 and
CCK are not only synthesised in the intestine but also released
locally by islet cells to exert autocrine or paracrine actions
(19, 20).
Independent benefits on beta-cell growth and survival
following upregulation of GLP-1 and CCK receptor activation
were verified (18, 34). Although additive effects were not
apparent in terms of protection against apoptosis, there were
clear benefits of combined receptor upregulation on beta-cell
proliferation. Interestingly, interactions between islet-derived
GLP-1 and CCK have been suggested to be important for beta-
cell survival, rather than growth (21). Our contrasting
observations may be linked to the experimental system
employed, as well as differences in duration and extent of
receptor activation. However, proliferative benefits of GLP-1Frontiers in Endocrinology | www.frontiersin.org 7and CCK in the current setting are fully supported by changes
in gene expression. As such, beta-cell regeneration is believed to
be controlled by glucose metabolism and metabolic demand (38),
with combination GLP-1 and CCK-8 treatment resulting in
distinct increases of glucose sensor glucokinase gene expression
(39). Combined treatment also resulted in a reduction in pro-
apoptotic NFkB and BAX gene expression in line with known
downstream actions of CCK (40). When viewed in conjunction
with previous observations (5, 25), these data provide a
compelling case to further explore the therapeutic potential of
GLP-1/CCK dual-acting hybrid peptides (26, 27).
To this end, [Lys12Pal]Ex-4/CCK was engineered as a long-
acting GLP-1 and CCK1 receptor agonist (Table 1), based on
earlier positive observations of pronounced bioactivity of a GLP-
1/CCK-8 fusion peptide and the pharmacodynamic benefits of
peptide acylation (27, 41). As such, [Lys12Pal]Ex-4/CCK
combines the key complementary glucose-lowering and satiety
actions of exendin-4 and CCK-8, possessing an exendin-4 like N-
terminus fused to a C-terminal CCK1 receptor agonist through
use of a polyether linking compound (Table 1). Consistent with
previous studies, activation of GLP-1 and CCK1 receptors by




FIGURE 3 | Effects of [Lys12Pal]Ex-4/CCK on food intake in mice. [Lys12Pal]Ex-4/CCK (25 nmol/kg bw, i.p.) was administered (A) 0, (B) 4, (C) 8 or (D) 12 h prior to
assessment of food intake in overnight (16 h) fasted C57BL/6 mice. (E) [Lys12Pal]Ex-4/CCK (25 nmol/kg bw, i.p.) was administered alone or together with either
exendin(9-39) or SR27897 (both at 25 nmol/kg bw) as well as in combination with both exendin(9-39) and SR SR27897. Food intake was recorded at regular
intervals over a 3-hour observation period. Values are mean ± SEM for 8 mice. *p < 0.05, **p < 0.01 and ***p < 0.001 compared with saline-treated control.
Dp < 0.05 and DDp < 0.01 compared with [Lys12PAL]Ex-4/CCK.May 2021 | Volume 12 | Article 674704





FIGURE 4 | Effects of [Lys12Pal]Ex-4/CCK on glucose tolerance and insulin secretion in C57BL/6 mice. Blood glucose and plasma insulin concentrations were
assessed following administration of [Lys12Pal]Ex-4/CCK (25 nmol/kg bw, i.p.) in combination (A, B) with glucose (18 mmol/kg bw, i.p.) or (C, D) 4 h, (E, F) 8 h,
(G, H) 12 h or (I, J) 24 h prior to glucose administration. 0-60 min glucose AUC values are also shown. Values are mean ± SEM for 8 mice. *p < 0.05, **p < 0.01
and ***p < 0.001 compared with glucose alone control.Frontiers in Endocrinology | www.frontiersin.org May 2021 | Volume 12 | Article 6747048
Tanday et al. An Acylated GLP-1/CCK Hybrid PeptideBD11 cells (5, 26). Given that [Lys12Pal]Ex-4/CCK is acylated at
Lys12 to promote albumin binding and prolong half-life, an
intervention which often perturbs bioactivity (41), equipotency
with exendin-4 is encouraging. To further probe insulinotropic
effects, [Lys12Pal]Ex-4/CCK was co-incubated with known
modulators of beta-cell function and shown to potentiate the
insulin releasing actions of glucose, alanine, elevated Ca2+ or the
phorbol ester PMA. Further to these in vitro effects, acute
administration of [Lys12Pal]Ex-4/CCK to mice inhibited
feeding activity, improved glucose tolerance, and potentiated
the plasma insulin response to glucose. Such actions were
protracted, with some effects even persisting when the peptide
was administered up to 24 hours previously, contrasting with
actions of native exendin-4 and CCK-8 which are relatively
short-lived under similar experimental conditions (16, 35).
Experiments employing pharmacological GLP-1 and CCK1
receptor antagonists perhaps suggested a very slight biasFrontiers in Endocrinology | www.frontiersin.org 9towards GLP-1 receptor signalling in mediating the biological
actions of [Lys12Pal]Ex-4/CCK, in agreement with previous
reports (27), but genuine prudence is required in terms of this
data interpretation. Thus, the recognised synergism between
GLP-1 and CCK receptor pathways (21–23) is not quantifiable
when employing knockout of individual receptor pathways.
Although informative, these antagonist studies are unable to
provide a complete picture of the undoubted importance of
synergy between GLP-1 and CCK1 receptor pathways for
[Lys12Pal]Ex-4/CCK mediated benefits (26, 27).
Encouraged by these observations, we embarked on a longer-
term in vivo study in mice that were administered low dose
injections of STZ daily over 14 days to compromise beta-cell
function in association with ad libitum access to high fat diet to
induce insulin resistance and beta-cell stress (33). The resulting
phenotype was characterised by failure of classical islet hypertrophy
and beta-cell compensation in HFF-STZ mice, culminating inA B
C D
E F
FIGURE 5 | Effects of [Lys12Pal]Ex-4/CCK on (A) body weight, (B) body weight change, (C) calorie consumption, (D) terminal non-fasting blood glucose as well as
terminal non-fasting plasma (E) insulin and (F) glucagon in HFF-STZ mice. (A–C) Parameters were measured at regular intervals over 28 days treatment with twice-
daily [Lys12Pal]Ex-4/CCK (25 nmol/kg bw, i.p) in HFF-STZ mice. (D–F) Parameters were measure on day 28, with plasma insulin and glucagon were measured by
RIA or ELISA, respectively. Values are mean ± SEM for 8 mice. *p < 0.05, **p < 0.01 and ***p < 0.001 compared with HFF-STZ diabetic control.May 2021 | Volume 12 | Article 674704
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injection of these mice with [Lys12Pal]Ex-4/CCK for 28 days led to
significant reductions in energy intake, body weight and blood
glucose levels, in keeping with upregulated GLP-1 and CCK1
receptor activity (9). Importantly, these beneficial effects were
apparent early in the treatment regimen and persisted
throughout, with no indication of desensitisation (42). This
highlights the long-acting nature and efficacy of [Lys12Pal]Ex-4/
CCK. Development of a specific assay to measure [Lys12Pal]Ex-4/
CCK in plasma, as well as tissue distribution, would be useful to
provide more precise details of in vivo bioavailability.
Improvements in glucose tolerance in HFF mice with STZ-
induced compromised beta-cells, although likely to be partially
dependent on weight loss (43), were associated with significantly
increased glucose-induced insulin concentrations. Indeed,
circulating and pancreatic insulin were substantially increased in
[Lys12Pal]Ex-4/CCK mice at the end of the 28-day study. It would
also have been useful to examine metabolic effects following an
oral nutrient challenge, but unfortunately that was not possible in
the current study. Interestingly, the characteristic insulin
resistance evoked by sustained high fat feeding (44) did not
appear to be appreciably improved by [Lys12Pal]Ex-4/CCK
intervention. Evidence for a small but significant enhancement
of AAC glucose was noted, but this modest effect could be related
to the fact that blood glucose levels in [Lys12Pal]Ex-4/CCK treated
mice were well below 5 mmol/l during the experiment. This
presumably resulted in activation of adaptive responses to
counter the hypoglycaemia induced by bolus injection ofFrontiers in Endocrinology | www.frontiersin.org 10exogenous insulin. In contrast to the small magnitude of this
effect, [Lys12Pal]Ex-4/CCK evoked particularly prominent
improvements in islet architecture in the HFF-STZ mice (19).
Such morphological benefits which were closely linked to
elevations in beta-cell proliferation (20, 34), in direct agreement
with our in vitro observations. We also observed reductions in
beta-cell apoptosis with sustained [Lys12Pal]Ex-4/CCK therapy
that would also contribute to improved islet architecture (21).
Furthermore, observed reductions in alpha-cell area and overall
alpha:beta cell ratios were paralleled by decreases in pancreatic and
plasma glucagon in the peptide treated mice. This observation fits
well with reported glucagonostatic effects of GLP-1 receptor
activation (45). However, it does contrast somewhat with the
reported direct glucagonotropic actions of CCK (8), and detailed
study of the overall impact of activation of GLP-1 and CCK1
receptors by [Lys12Pal]Ex-4/CCK in this regard is required.
Despite the obvious therapeutic attractiveness of [Lys12Pal]Ex-
4/CCK, there are a number of significant matters that need to be
considered with regards possible translation towards clinical
development. Although initial fears of increased pancreatitis risk
with GLP-1mimetic therapy in humans has now been fully allayed
(46), extremely high doses of CCK are employed to create
experimental rodent models of pancreatic inflammation (47).
However, it should be noted that the CCK1 receptor is
expressed at much higher levels in pancreatic acinar cells of
rodents than humans (48). Moreover, 28 days treatment with
[Lys12Pal]Ex-4/CCK did not lead to any obvious detrimental
pancreatic histopathological findings in our study. As notedA B C D
E F G H
FIGURE 6 | Effects of [Lys12Pal]Ex-4/CCK on (A, B) glucose tolerance, (C, D) insulin secretion, (E, F) as well as pancreatic (G) insulin and (H) glucagon content in
HFF-STZ mice. Parameters were measured following 28 days twice-daily treatment with [Lys12Pal]Ex-4/CCK (25 nmol/kg bw, i.p). (A, B) Blood glucose and
(C, D) plasma insulin was measured prior to and after administration of glucose alone (18 mmol/kg, i.p) at t = 0 min. (E, F) Blood glucose was measured after
administration of insulin (25 U/kg bw, i.p) at t = 0 min. (G, H) Pancreatic insulin and glucagon content were measured by RIA or ELISA, respectively, following
pancreatic protein extraction. Values are mean ± SEM for 8 mice. *p < 0.05, **p < 0.01 and ***p < 0.001 compared with HFF-STZ diabetic control.May 2021 | Volume 12 | Article 674704
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[Lys12Pal]Ex-4/CCK were consistently linked to correction of
the diabetes phenotype. In addition, previous studies employing
sustained co-activation of GLP-1 and CCK1 receptors in rodent
models reported no effect, or even reductions, in amylase and
lipase secretion (25, 26). The possible impact of combined GLP-1
and CCK1 receptor activation on gastric emptying would also
need to be considered (49, 50). However, we observed no obvious
behavioural changes in [Lys12Pal]Ex-4/CCK treated mice. Finally,
there is a suggestion that GLP-1 mimetics suppress CCK secretion
in humans, leading to adverse gallbladder events (51). Thus, dual
activation of both receptor pathways by [Lys12Pal]Ex-4/CCK
could help to alleviate this potential problem.
In conclusion, the present study has reaffirmed clear benefits
of combined GLP-1 and CCK1 receptor signalling. [Lys12Pal]Ex-
4/CCK, created as a long-acting, dual GLP-1 and CCK1 receptor
activating hybrid peptide, displayed prominent antidiabetic
actions in HFF-STZ mice that were directly linked to improved
islet morphology and beta-cell function. Such benefits were also
coupled to induction of satiety and sustained reductions in body
weight. These exciting preclinical observations necessitate the
further consideration of combined GLP-1 and CCK1 receptor
activation as a potential treatment option for the increasing
numbers of people living with obesity and related diabetes.Frontiers in Endocrinology | www.frontiersin.org 11DATA AVAILABILITY STATEMENT
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FIGURE 7 | Effects of [Lys12Pal]Ex-4/CCK on pancreatic islet morphology as well as beta-cell proliferation and apoptosis in HFF-STZ diabetic mice. (A) Islet-,
(B) beta- and (C) alpha-cell areas, (D) alpha:beta ratio, (E) percentage of glucagon positive centrally stained cells as well as beta-cell (F) proliferation and (G)
apoptosis were measured following 28 days twice-daily treatment with [Lys12Pal]Ex-4/CCK (25 nmol/kg bw, i.p). Islet morphology was assessed using CellF image
analysis software, with beta-cell proliferation and apoptosis measured Ki-67 or TUNEL staining, respectively. (H-J) Representative islet images (x40 magnification)
show (H) insulin (red) and glucagon (green), (I) insulin (red) and Ki-67 (green) or (J) insulin (red) and TUNEL (green) from each treatment group. Values are mean ±
SEM for 8 mice. *p < 0.05, **p < 0.01 and ***p < 0.001 compared with HFF-STZ diabetic control. DDp < 0.01 and DDDp < 0.001 compared with lean control.May 2021 | Volume 12 | Article 674704
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